SurModics

The Federal Trade Commission and several federal agencies have declined to appeal a court ruling, bringing Surmodics a step closer to the expected completion of the takeover by a GTCR subsidiary. Surmodics said it intends to push the deal forward promptly once the regulatory situation is clarified, while a preliminary injunction still prohibits closing until Nov. 17, 2025, 5:00 p.m. CT. The transaction remains subject to other contractual closing conditions, including the absence of material legal obstacles or a material adverse effect on the company. The stock reacted positively in premarket trading, rising about 2.9 percent. » More on de.investing.com

US regulators announced they will not appeal the court decision that rejected a preliminary injunction against the merger, clearing the way for completion of the acquisition of Surmodics by a subsidiary of GTCR. Surmodics shares rose sharply in the prior week; however, the transaction remains subject to an existing temporary injunction and contractual closing conditions. The company continues to cite the fulfillment of legal/regulatory requirements and the absence of material adverse effects as prerequisites for the final closing. » More on de.investing.com

Surmodics' stock climbed about 50% after a U.S. district court denied the FTC's request for a preliminary injunction against the planned takeover by GTCR. The decision removes a major hurdle, but a temporary restraining order remains in effect until no later than November 17 at 5:00 p.m. Central Time, and additional closing conditions and regulatory reviews still must be satisfied. Surmodics says it remains confident the deal will benefit physicians, patients and customers. » More on de.investing.com